| Insulin-like peptide 5 is associated with insulin resistance in women with polycystic ovary syndrome. | Insulin-like peptide 5 is associated with insulin resistance in women with polycystic ovary syndrome.
Chen Y, Chen J, Li Y, Wu Y, Wu X, Zhang H, Zhang Z. | 06/21/2023 |
| Insulin-like peptide 5 (INSL5) positively correlates with anti-Mullerian hormone (AMH) in women with the polycystic ovary syndrome: a case-control study. | Insulin-like peptide 5 (INSL5) positively correlates with anti-Müllerian hormone (AMH) in women with the polycystic ovary syndrome: a case-control study.
Chen Y, Deng M, Chen Z, Han S, Chen J, Zhang H, Wang Q, Jin X, Liu W, Zhang Z., Free PMC Article | 11/5/2022 |
| Expression of Cytokine-Coding Genes BMP8B, LEFTY1 and INSL5 Could Distinguish between Ulcerative Colitis and Crohn's Disease. | Expression of Cytokine-Coding Genes BMP8B, LEFTY1 and INSL5 Could Distinguish between Ulcerative Colitis and Crohn's Disease.
Skok DJ, Hauptman N, Jerala M, Zidar N., Free PMC Article | 02/12/2022 |
| Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling. | Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling.
Li SB, Liu YY, Yuan L, Ji MF, Zhang A, Li HY, Tang LQ, Fang SG, Zhang H, Xing S, Li MZ, Zhong Q, Lin SJ, Liu WL, Huang P, Zeng YX, Zheng YM, Ling ZQ, Sui JH, Zeng MS., Free PMC Article | 09/25/2021 |
| This study provides novel insights into possible autocrine/paracrine roles of INSL5 in the intestinal tract. | INSL5 activates multiple signalling pathways and regulates GLP-1 secretion in NCI-H716 cells.
Ang SY, Evans BA, Poole DP, Bron R, DiCello JJ, Bathgate RAD, Kocan M, Hutchinson DS, Summers RJ. | 09/14/2019 |
| High serum INLS5 levels are associated with metabolic diseases in women with polycystic ovary syndrome. | Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome.
Bicer M, Alan M, Alarslan P, Guler A, Kocabas GU, Imamoglu C, Aksit M, Bozkaya G, Isil AM, Baloglu A, Aslanipoiur B, Calan M. | 07/13/2019 |
| The R27S (B5Ser) mutant variant of INSL5 was evaluated as a potential antagonist of the native RXFP4 receptor, yet was found to match the potency and maximal efficacy to the native hormone. This informs that the R27S phenotype is not directly linked to the receptor activity of the peptide, but likely affects endogenous hormone production or secretion. | Synthesis and Characterization of the R27S Genetic Variant of Insulin-like Peptide 5.
Zaykov AN, Gelfanov VM, Liu F, DiMarchi RD. | 03/23/2019 |
| Mass spectral analysis of purified enteroendocrine cells and tissue homogenates identified the exact sequence of A and B chains of INSL5 endogenously expressed in L-cells. | Liquid chromatography/mass spectrometry based detection and semi-quantitative analysis of INSL5 in human and murine tissues.
Kay RG, Galvin S, Larraufie P, Reimann F, Gribble FM., Free PMC Article | 09/8/2018 |
| analysis of the interaction mechanism of INSL5 with its receptor RXFP4 | Interaction mechanism of insulin-like peptide 5 with relaxin family peptide receptor 4.
Hu MJ, Wei D, Shao XX, Wang JH, Liu YL, Xu ZG, Guo ZY. | 05/20/2017 |
| High serum INSL5 is associated with obesity in men. | Insulin-Like Peptide 5 Interacts with Sex Hormones and Metabolic Parameters in a Gender and Adiposity Dependent Manner in Humans.
Wagner IV, Flehmig G, Scheuermann K, Löffler D, Körner A, Kiess W, Stumvoll M, Dietrich A, Blüher M, Klöting N, Söder O, Svechnikov K. | 03/18/2017 |
| The C-terminus of the B-chain of human INSL5 is critical for cognate RXFP4 receptor activity. | The C-terminus of the B-chain of human insulin-like peptide 5 is critical for cognate RXFP4 receptor activity.
Patil NA, Bathgate RAD, Kocan M, Ang SY, Tailhades J, Separovic F, Summers R, Grosse J, Hughes RA, Wade JD, Hossain MA. | 12/17/2016 |
| Insl5 is an orexigenic hormone released from colonic L-cells, which promotes appetite during conditions of energy deprivation. | Insulin-like peptide 5 is an orexigenic gastrointestinal hormone.
Grosse J, Heffron H, Burling K, Akhter Hossain M, Habib AM, Rogers GJ, Richards P, Larder R, Rimmington D, Adriaenssens AA, Parton L, Powell J, Binda M, Colledge WH, Doran J, Toyoda Y, Wade JD, Aparicio S, Carlton MB, Coll AP, Reimann F, O'Rahilly S, Gribble FM., Free PMC Article | 11/8/2014 |
| electrostatic interactions between INSL5 and RXFP4 | Identification of important residues of insulin-like peptide 5 and its receptor RXFP4 for ligand-receptor interactions.
Wang XY, Guo YQ, Shao XX, Liu YL, Xu ZG, Guo ZY. | 10/11/2014 |
| High INSL5 expression is associated with enteroendocrine cells of the neuroendocrine tumors. | INSL5 is a novel marker for human enteroendocrine cells of the large intestine and neuroendocrine tumours.
Thanasupawat T, Hammje K, Adham I, Ghia JE, Del Bigio MR, Krcek J, Hoang-Vu C, Klonisch T, Hombach-Klonisch S. | 01/11/2014 |
| INSL5 may be a unique marker of colorectal enteroendocrine cells, and INSL5-RXFP4 signaling might play a role in an autocrine/paracrine fashion in the colorectal epithelium and rectal neuroendocrine tumors. | INSL5 may be a unique marker of colorectal endocrine cells and neuroendocrine tumors.
Mashima H, Ohno H, Yamada Y, Sakai T, Ohnishi H. | 09/28/2013 |
| Observational study of gene-disease association. (HuGE Navigator) | Investigation of genetic susceptibility factors for human longevity - a targeted nonsynonymous SNP study.
Flachsbart F, Franke A, Kleindorp R, Caliebe A, Blanché H, Schreiber S, Nebel A. | 12/5/2010 |
| The hydrogen-bond network and electrostatic interactions between charged groups in INSL5 by NMR-monitored temperature and pH titrations was characterized. | Structure of human insulin-like peptide 5 and characterization of conserved hydrogen bonds and electrostatic interactions within the relaxin framework.
Haugaard-Jönsson LM, Hossain MA, Daly NL, Craik DJ, Wade JD, Rosengren KJ. | 01/21/2010 |
| Insulin-like peptide 5 is an endogenous ligand for GPCR142 | INSL5 is a high affinity specific agonist for GPCR142 (GPR100).
Liu C, Kuei C, Sutton S, Chen J, Bonaventure P, Wu J, Nepomuceno D, Kamme F, Tran DT, Zhu J, Wilkinson T, Bathgate R, Eriste E, Sillard R, Lovenberg TW. | 01/21/2010 |